Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:41:44.154Z.
Consensus retrieved: 2026-10-06T11:10:56.877Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:41:44.154Z.
Quote observation: 2026-10-06T14:38:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2fb444e1e26cbd5896b6e324764cb09ba059118d447e0aa37aaedcb3e28ce7b2
Forward PE Ratio (N/A) = Dated Quote Price ($0.42) / Consensus Forward EPS ($-1.09)
FORWARD PE RATIO
N/A
Ensysce Biosciences, Inc.
Market Cap
$6.47M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.47M | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.27M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.83M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | N/A |
| Femasys Inc. (FEMY)vs › | $6.07M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.10M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.42, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.09 | $-1.09 – $-1.09 | 1 | n/m |
| 2027-12-31 | $-0.06 | $-0.06 – $-0.06 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
